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Abstract
Alzheimer’s disease was first discovered in 1906 by Alois Alzheimer. It is a neurodegenerative disease characterized
by the buildup of toxic amyloid plaque and intracellular neurofibrillary tangles, which results in the progressive loss of
cognitive function and memory. Since its discovery, the disease has become a growing health concern, particularly in the
developed world, where the ageing demographics have contributed to an increase in its prevalence and incidence. The
earliest research into the disease focused on neurochemical analyses and resulted in the formulation of the cholinergic
hypothesis. The mechanism of disease was explained as the degeneration of the cholinergic system and a reduction in
acetylcholine. While much data supports this hypothesis, it fails to explain the accumulation of amyloid plaque, a hallmark of the disease. Analysis of the genetic factors in familial Alzheimer’s disease, and the discovery of the higher risk
for Alzheimer’s disease amongst individuals with Down’s syndrome led to the more comprehensive amyloid cascade
hypothesis.The failure of both amyloid centric drugs and cholinesterase inhibitors to have a significant impact on disease
progression has caused some to have rejected both these hypotheses to focus on other possible causes. However,
there is undoubtedly a wealth of data in support of both the cholinergic hypothesis and the amyloid cascade hypothesis.
Understanding the functional relationship between the cholinergic system and the formation of beta amyloid plaques
may lead to a greater understanding of the mechanism of disease and provide a target for more effective therapy.
Introduction
Alzheimer’s disease was first identified by Alois Alzheimer in
1906. However not until the 1970’s did it become a major and
significant area of research. Since that time much has been
discovered about the mechanisms of the disease, however the
precise biological processes in the disease are mostly unknown
and the large variance in its progression amongst patients with
the disease needs to be better understood.
Alzheimer’s disease is a neurodegenerative disease that effects
memory, behavior and eventually leads to death within an average of 8 years of diagnosis, the last three of which are typically
spent with full time care or in an institution.
The changing demographics worldwide and with the baby boom
generation reaching ages 70 and beyond has led Alzheimer’s
disease to become one of the biggest healthcare concerns in
the developed world. This greater prevalence and incidence of
Alzheimer’s disease, the largest cause of dementia, has created a
huge burden on society.
Millions of Americans have Alzheimer’s disease and other forms
of dementias. An estimated 5.4 million Americans of all ages had
Alzheimer’s disease in 2016. One in nine people aged 65 years
or older and about one third (32%) of people aged 85 and older
have the disease (Herbert et al., 2013).
The future projections for Alzheimer’s disease are equally bleak.
Approximately 476,000 people will develop the disease in the
United States in 2016, with the numbers increasing dramatically
with age. There will be 63,000 new cases among people aged 65
to 74 and 241,000 new cases among people aged 85 and older.
Because of the ageing demographics in the United States, these
numbers are projected to double by 2050 (Herbert et al., 2001).

Alzheimer’s disease is one of the leading causes of both mortality and morbidity in the United States. It is currently the sixth
leading cause of death for those 65 years and older. According
to data from the National Center for Health Statistics of the
Centers for Disease Control and Prevention (CDC), 84,767
people died from it in 2013. These numbers only consider
those who have cause of death listed as Alzheimer’s disease on
their death certificate. Death certificates for individuals with
Alzheimer’s disease often list other acute conditions, such as
pneumonia, as the primary cause of death and therefore death
due to Alzheimer’s is most likely underreported.
The cost of the disease is very substantial, both in terms of the
value of the unpaid caregiving for Alzheimer’s disease which has
been estimated at $221.3 billion in 2013, and the total payments
made which in 2016 was estimated at $236 billion. Overall the
cost of healthcare, long term care and hospice care for individuals with the disease makes it one of the costliest chronic
diseases to society (Hurd et al., 2013).
Alzheimer’s disease is characterized by a gradually worsening
ability to remember new information. This occurs because the
first neurons to be damaged and destroyed are in the area of
the brain responsible for creating new memories. As the disease
causes the destruction of neurons in other regions of the brain,
symptoms worsen and individuals experience other difficulties
such as challenges in problem solving and planning, confusion
with time and place, decreased and poor judgement, and withdrawal from social activities and work.
There are about 100 billion neurons in the adult healthy brain.
During the development of Alzheimer’s disease, the connections and synapses between neurons is hindered and the overall
number of neurons decrease. The destruction of neurons and
the disruption of the cellular neuronal circuits lead to many of
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the symptoms. The brains of people with advanced Alzheimer’s
disease show inflammation, dramatic shrinkage from cell loss
and widespread debris from dead and destroyed neurons. Some
of these brain changes can begin 20 years prior to the onset of
symptoms for the disease (Villemagne et al., 2013).
No simple test currently exists for diagnosis of Alzheimer’s disease, rather an individual’s physician together with the help of a
neurologist will use a variety of methods to assist in a diagnosis.
These include obtaining a family history and medical history of
the patient which may include psychiatric, cognitive and behavioral histories. In addition, diagnosis is often aided by conducting
cognitive tests and physical and neurological examinations. Finally,
a physician will typically use blood tests and brain imaging to rule
out other possible causes of behavioral and memory changes
such as tumor formation or nutrient deficiencies.
Much research has focused on a potential precursor to
Alzheimer’s disease known as Mild Cognitive Impairment (MCI).
An individual with Mild Cognitive Impairment will experience
mild but measurable changes in thinking abilities that are noticeable to friends and families of the affected person but that
do not affect the person’s ability to carry out normal everyday
functions and activities (Roberts & Knopman, 2013). It is estimated that about 20% of people over the age of 65 have Mild
Cognitive Impairment. Recent studies have shown that an average of 32% of people with MCI will develop Alzheimer’s disease
within 5 years. However, some with MCI will see their cognitive
decline stabilize, and in some cases, they may even return to
normal cognition (Ward et al., 2013).
In a small percent of those diagnosed with Alzheimer’s disease
the development of the disease can be attributed to genetic
mutations.Three genes have been implicated in its development.
These are the genes which encode for the amyloid precursor
protein (APP), the genes for presenilin-1 and for presenilin-2.
Mutations in both the APP gene and the presenilin-1 gene result
in guaranteed development of the disease, while a mutation in
the presenilin-2 gene leads to a 95% chance of its development.
Individuals with mutations in any of these three genes will usually develop symptoms as young as age 30, unlike the vast majority
of Alzheimer’s cases, which are late onset where symptoms typically develop at age 65 and over (Bekris et al., 2010).
People with Down syndrome are born with an additional copy
of chromosome 21 and have a greater risk of developing all
forms of dementia including Alzheimer’s disease. Studies have
found that more than 75% of people with Down Syndrome
aged 65 and over have Alzheimer’s. While the exact relationship
between Down Syndrome and Alzheimer’s is not entirely clear,
one possible explanation might be that the gene that codes for
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amyloid precursor protein is located on chromosome 21 and
the additional copy of this gene increases the likelihood of the
development of the plaques associated with the amyloid precursor protein. By age 40 most people with Down Syndrome have
high levels of beta amyloid plaques in their brains, a marker for
Alzheimer’s disease (Lott & Dierssen, 2010).
Besides for the genetic factors in Alzheimer’s disease much research has been conducted on the effects of environmental and
modifiable risk factors. Studies have shown that regular physical
activity, and management of cardiovascular risk factors such as
obesity, smoking and high blood pressure reduce the risk of the
development of Alzheimer’s disease and dementia. There is also
evidence that a healthy lifestyle and diet as well as continued
engagement in learning can prevent cognitive decline in old age
(Baumgart et al., 2015).
Current treatment options for Alzheimer’s disease are limited.
None of the pharmacological treatments available cures or
stops the damage the disease causes to the brain. The six drugs
that have thus far been approved by the U.S Food and Drug
Administration (FDA) focus primarily on increasing the levels
of neurotransmitter present in the brain. While this helps deal
with the symptoms of Alzheimer’s disease such as memory loss
and reduced cognitive capacity, these drugs don’t deal with the
underlying issues in the disease, and their effectiveness is limited
to the early stages of the disease.
This paper attempts to review some of the complex molecular
mechanisms involved in Alzheimer’s disease. It will explore the
current research on the molecular mechanisms in Alzheimer’s
disease to better understand the development of the disease
and the wide variance in disease progression, and explain possible areas of future research in the development of more effective therapeutic agents.

Methods
This study was performed through the analysis of various original and peer reviewed articles which were accessed using databases such as the Touro Database, PubMed, and Google Scholar.
The research collected in this study was used to understand the
molecular processes in Alzheimer’s disease, and to evaluate the
various hypotheses postulated in the formation of the disease.

Discussion
Since the systematic biochemical analysis of patients with
Alzheimer’s began in the early 1970’s much knowledge has been
acquired concerning the possible mechanisms responsible for
the disease.The earliest research into neurochemical abnormalities that are present in Alzheimer’s disease led to the formulation of the cholinergic hypothesis.

Molecular Mechanisms of Alzheimer’s Disease

Cholinergic Hypothesis
Acetylcholine was the first neurotransmitter to be identified
and is the neurotransmitter used in all cholinergic neurons. It is
fundamental in both the central nervous system (CNS) and the
peripheral nervous system (PNS).
Successful neurotransmission of acetylcholine is dependent on
proteins needed for its synthesis, transport, degradation and reuptake. Acetylcholine synthesis takes place in the cytoplasm of
cholinergic cells. The enzyme, choline acetyltransferase (ChAT)
catalyzes the combination reaction of dietary choline and AcetylCoA, generated by the mitochondria, to form the product acetylcholine. Three forms of the ChAT enzyme have been found in
humans. Formation of acetylcholine is followed by its transfer to
the synaptic vesicles before release.This step is enabled by the vesicular acetylcholine transporter (VAChT). When the cholinergic
neurons are depolarized, acetylcholine is released by exocytosis
into the synaptic cleft. On the post synaptic neuron, acetylcholine
can activate both muscarinic and nicotinic receptors. Nicotinic
ACh receptors are ion gated channels which are selective for
cations including sodium, potassium, and calcium. Nicotinic receptors are made up from a combination of five different subunits.
The large variance in the properties and functions of the different
nicotinic receptors is a direct result of the many different possible
combinations of subunits that form each receptor. In the PNS the
activation of these receptors results in the transmission of the
signal to ganglion cells and the innervation of muscles and glands.
In the CNS the role of nicotinic receptors is regulatory rather
than purely the transmission of excitatory or inhibitory signals.
In the PNS the nicotinic receptors are mostly located on the
post synaptic neuronal membrane, where they are activated by
acetylcholine and facilitate the transmission of signals. However,
in the CNS the receptors are mostly located on the pre-synaptic
neuronal membrane where their activation regulates the release
of acetylcholine and other neurotransmitters into the synapse.
The activation of these receptors results in an increase in calcium
levels in the presynaptic neuron, which is a crucial step in the
exocytosis of neurotransmitters such as GABA, glutamate, dopamine and serotonin into the synapse. Muscarinic receptors are
G-protein coupled receptors, and unlike the nicotinic receptors,
their role is largely in the transmission of signals. Five isoforms of
the receptor have so far been identified. M1, M3 and M5 are excitatory receptors and their activation results in the formation of
second messengers by phospholipase C which results in closure
of K+ channels enabling the greater depolarization of the cell
and the transmission of signal down the axon. M2 and M4 are
inhibitory and their activation has the opposite effect.They result
in the inhibition of adenylyl cyclase which leads to lower levels
of cyclic adenosine monophosphate (cAMP) and promotes the
inhibition of [Ca]++ channels diminishing cell excitability.

In the synaptic cleft acetylcholine is broken down to its components Acetyl-CoA and choline by the enzyme acetylcholinesterase (AChE). AChE is one of the most kinetically effective
enzymes. It is able to catalyze the breakdown of 5000 molecules
of acetylcholine per second. The choline transporter, CHT1, facilitates the uptake of choline, that is produced by the breakdown of acetylcholine by AChE, into the presynaptic neuron.
This transporter is also the source of the choline used in acetylcholine synthesis and it therefore plays a crucial role in the
recycling of acetylcholine (Fig. 1, Ferreira Vieira et al., 2016).

Figure 1 Schematic representation of biological aspects involving
acetylcholine neurotransmission. (Ferreira Vieira et al., 2016)
Early research into Alzheimer’s disease showed reduced activity of choline acetyltransferase in the amygdala, hippocampus
and cortex of patients with the disease. In one such study, the
levels of the enzyme responsible for acetylcholine synthesis in
patients with the disease was found to be lower than 10% of the
normal activity seen in the control group. Similarly, the levels of
acetylcholinesterase in the same brain regions were markedly
lower in patients with Alzheimer’s disease (Davies & Maloney
1976).
Further studies showed that in addition to the decreased activity of the enzymes responsible for acetylcholine synthesis, the
levels of acetylcholine uptake by neurons in the frontal cortex
and in the hippocampus, were significantly lower in patients
with Alzheimer’s disease. In the frontal cortex, the transport
of choline into synaptosomes was reduced by 50% and an even
greater reduction of 80% was seen in the hippocampus. Further
evidence of the loss of cholinergic function in the uptake of
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choline in Alzheimer’s disease is seen in the lower densities of
the presynaptic high affinity choline uptake carrier (HACU) in
both the cortex and hippocampus (Rylett et al., 1983; Pascual
et al., 1991).
Other studies have shown there to be a reduction in the number of nicotinic and muscarinic M2 acetylcholine receptors in
Alzheimer’s disease brains and there is evidence for the disruption of the M1 receptors and their G-proteins which effects the second messenger systems and transmission of signals
(Whitehouse et al., 1988).
The cholinergic hypothesis of Alzheimer’s disease was also evidenced by the reduction in the amount of acetylcholine released
from neurons in the brains of affected patients. An experiment
conducted on brain tissue of both controls and patients with
the disease collected with short post mortem delay, showed
a significant reduction in tritium (3H-acetylcholine) release
during potassium stimulation, as compared with the controls
(Nilsson et al., 1986).
In addition, the loss of cholinergic neurons as a result of the
neurodegeneration caused by Alzheimer’s has further implicated the cholinergic system in the etiology of the disease. In
particular, the selective degeneration of neurons in the nucleus
basalis of Meynert, a significant source of neurons which are
fundamental in the cholinergic innervation of the cerebral
cortex, explains the reduction in the levels of acetylcholine in
individuals with Alzheimer’s disease (Whitehouse et al., 1982).
It has also been demonstrated that the cholinergic system plays
a role in memory and in learning. The loss of the neurons in
the nucleus basalis of Meynert has been correlated with the
impaired memory and cognitive abilities seen in patients with
Alzheimer’s disease. The effects on the cholinergic system has
also been shown to result in the many behavioral and psychological symptoms seen in individuals with the disease. Emotional
processing deficits associated with Alzheimer’s disease may
be caused by loss of cholinergic function in the areas of the
amygdala and frontal cortex. Apathy and depression as well as
disturbance in sleep cycle are symptoms commonly found in
patients with Alzheimer’s disease. It has been postulated that
the degeneration of cholinergic neurons and the resulting loss
of regulation of neurotransmitters, including dopamine and serotonin, is responsible for the many psychiatric symptoms observed. Moreover, cholinesterase inhibitors, the primary focus
of the current pharmacologic agents available for the treatment
of Alzheimer’s disease have shown to improve many of the psychiatric symptoms. Clinical trials conducted on affected patients,
reported reduced delusions, stress, apathy and depression in the
treated group (Ferreira et al., 2016; Pinto et al., 2011).
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There is much research that shows the link between the cholinergic system and Alzheimer’s disease.The neurodegeneration of
neuronal cells critical in the cholinergic system, the reduction in
the enzymes responsible for the synthesis of acetylcholine, and
lower levels of proteins that facilitate choline uptake in neuronal cells that is seen in the brains of patients with Alzheimer’s
disease, together with the role that the cholinergic system plays
in memory and learning have contributed to the formulation of
the cholinergic hypothesis. However there remains some inconsistencies in this hypothesis that suggest the role of the cholinergic system in the disease needs to be better understood.
Although cholinergic loss seems to correlate with cognitive
impairment, other factors such as loss of synapses and pyramidal cells may also be responsible for the cognitive decline.
Additionally, some patients with Alzheimer’s disease do not
show the large decreases in ChAT activity that would be expected. Moreover, patients with inherited olivopontocerebellar
activity have levels of ChAT which are reduced to similar levels
as those seen in Alzheimer’s patients yet they don’t experience
the decline in cognition and memory that would be expected.
An expectation of the cholinergic hypothesis would be that
drugs that restore cholinergic function to the brain regions effected by Alzheimer’s disease would improve and reverse the
cognitive symptoms seen in the disease. Five drugs have been
approved by the FDA for Alzheimer’s disease. Four of these
drugs are cholinesterase inhibitors and one is a receptor antagonist. The cholinesterase inhibitors have shown limited success
in clinical trials and are mostly able to merely delay the progression of the disease. The failure of the cholinesterase inhibitors
to cure Alzheimer’s disease was seen by some as the strongest
evidence against the cholinergic hypothesis.
Many researchers have continued to explore the role of neurotransmission in the disease because of the acetylcholine
dysfunction seen in the brains of Alzheimer’s disease patients.
However, the inconsistencies with the cholinergic hypothesis
have resulted in a shift in the focus of much of the more recent research towards two of the hallmarks of the disease, the
buildup of beta amyloid plaques in the extracellular space, and
the intracellular formation of neurofibrillary tangles (Craig et al.,
2011; Francis et al., 1999).

Amyloid Cascade Hypothsis
The origins of the Amyloid Cascade Hypothesis lie in the sequencing of the Aβ extracted from cerebral blood vessels
and the brain parenchyma of Alzheimer’s disease patients. The
identification of the Aβ sequence led to the sequencing of the
amyloid precursor protein gene (APP). This gene located on
chromosome 21 encodes the holoprotein that is cleaved first by
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the β-amyloid cleaving enzyme and then by γ-secretase to form
the Aβ peptide. (Masters et al., 1985; Kang et al., 1987; Hussain
et al., 1999). The essence of the amyloid cascade hypothesis is
that the increased production or decreased clearance of the
Aβ peptides causes the disease. Aggregation of the hydrophobic
Aβ40 and Aβ42 peptides results in the formation of insoluble
plaque which triggers a cascade of changes ultimately resulting
in cell death and the symptoms of the disease.
Human APP belongs to a family of type I transmembrane glycoproteins that also includes the similar amyloid precursor like
proteins 1 and 2 (APLP1 and APLP2). These proteins are functionally the same as the APP but they lack the Aβ sequence. The
APP gene is highly conserved and several alternatively spliced
isoforms of APP have been identified in humans. Invertebrates
such as the fruit fly D. melanogaster and the worm C. elegans
contain paralogs of the amyloid precursor protein, amyloid protein precursor-like (APPL) and APP-like 1, (APL-1). The zebrafish genome encodes two variants of APP, Appa and Appb. All of
these proteins share domains that are highly conserved in both
the large extracellular domains and in the shorter cytoplasmic
domain (Nicolas & Hassan, 2014).

Figure 2 The domain structure of APP family members in model
organisms. All APP homologs contain the extracellular domains E2, an
acidic domain (Ac), a copper binding domain (CuBD), and a heparin
binding domain (HBD). A kunitz protease inhibitor domain (KPI) is
found only in the APP and APLP-2 forms of the protein and the Aβ
sequence is only present in APP. The most highly conserved domain
across species is the intracellular YENPTY domain (Nicolas & Hassan,
2014).
APP can undergo two types of processing depending on the
secretases that cleave it. In the non-amyloidogenic pathway APP
is cleaved within the Aβ sequence by α-secretase forming the
sAPPα extracellular protein and the membrane bound αAPPCT.The membrane bound protein is then cleaved by γ-secretase
forming P3 peptide and amyloid precursor protein intracellular
domain (AICD).
In the amyloidogenic pathway,APP is first cleaved by β-secretase
forming the soluble sAPPβ protein and the C-terminal membrane bound fragment βAPP-CTF. The subsequent cleavage of

the βAPP-CTF fragment by γ-secretase forms the Aβ peptide
and the amyloid precursor intracellular domain (ACID). The
release of the Aβ peptide by γ-secretase is thought to be fundamental to Alzheimer’s disease pathology, and the aggregation
of these insoluble and toxic protein fragments results in the formation of the senile plaque that is a hallmark of the disease. In
the earliest and most direct elucidation of the amyloid cascade

Figure 3 proteolytic processing of APP (Nicolas & Hassan, 2014).
hypothesis the aggregation of the Aβ peptide was explained as
critical event in the development of Alzheimer’s disease. The
accumulation of the peptide was seen as both a cause of cell
death and as a crucial step in the hyper-phosphorylation of Tau
proteins leading to the formation of intracellular neurofibrillary
tangles (Hardy & Higgins, 1992).
Critical evidence for the ACH comes from human genetics. The
observation that the Aβ peptide deposited in elderly Down’s
syndrome patients, was the same as that found in patients with
Alzheimer’s suggested that a gene on chromosome 21 was
central to the development of the disease (Glenner & Wong,
1984a). Later studies on a family with a history of early onset
Alzheimer’s provided further evidence for a genetic link in the
disease, and was the basis for much of the research that followed. These studies revealed a missense mutation in the APP
gene that resulted in a V717I amino acid substitution in the
protein product. The position of the substitution, just upstream
from the carboxyl terminal cleavage site of the Aβ peptide, provided further evidence for the role of Aβ peptide in the etiology
of the disease (Goate et al., 1991).
The link between mutations in the presenilin 1 and presenilin 2
genes, that encode a part of the γ-secretase mutiprotein complex, and the development of the disease has likewise provided
support for the amyloid cascade hypothesis.
There are now hundreds of mutations to the PSEN-1, PSEN-2
and APP genes that are known to cause early onset familial AD
(FAD).These mutations effect the formation and accumulation of
amyloid plaque in several ways. Some of these mutations result in
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the extension of the C-terminal side of the Aβ peptide, others increase the overall ratio of the longer less soluble Aβ peptides to
the shorter more soluble forms, and some are directly responsible for an increase in the aggregatory properties of the protein.
In addition to the effects of these three genes on familial
Alzheimer’s disease, there are also genes that are connected
to sporadic Alzheimer’s disease (SAD). There are three major
alleles of the APOE gene in the human population (Nickerson et
al., 2000).These are APOE2, APOE3 and APOE4. A heterozygous
APOE4 carrier has a four-fold increased risk for the disease
as compared with the homozygous APOE3 genotype. The homozygous APOE4 genotype has an even more drastic 12 fold
increase in risk. Conversely, a carrier of the APOE2 gene has
a reduced risk of the disease (Verghase et al., 2011). The ApoE
protein is believed to have a role in the deposition of the amyloid plaques. Furthermore, there are specific mutations in the
APP gene that result in the protection against Alzheimer’s disease, with the evidence suggesting that they disrupt the ability
to form the Aβ peptides.

Figure 4 Amyloid precursor proteins. The diagram shows both the
β- secretase and γ-secretase cleavage sites and protective and
pathogenic mutations (Karran & De Strooper, 2016).
While many of the above studies have shown a link between the
genes involved in the formation of the Aβ peptides and the development of the disease, like the cholinergic hypothesis there
remain some inconsistencies and unanswered questions. These
questions have led many to believe that rather than being the
central mechanism in the development of Alzheimer’s disease,
the formation of amyloid plaque may just be one of several factors that contribute to its development.
Much to the frustration of the proponents of the ACH, the amyloidocentric drugs have failed to produce the results that would
have been expected according to the hypothesis.The phase three
clinical trials of 6 of these drugs have provided disappointing
results. Triampirosate, a small molecule drug that prevents the
aggregation of Aβ peptide showed no significant effect on cognition and memory during the clinical trials. Similarly no significant
effect on primary outcomes were seen in the trials of Tarenflurbil,
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a γ-secretase modulator that reduces the ratio of aggregatory
Aβ peptide to the shorter more soluble form. The only limited
success in this class of drug for the treatment of Alzheimer’s disease, was Solanezumab, a monoclonal antibody directed at the
amyloid plaque protein. In its phase three clinical trials there was
a significant improvement in cognitive abilities. In an extension
trial, these positive effects on cognition were sustained over a
two-year period raising hope and providing some evidence for a
disease modifying effect (Karran & De Strooper, 2016).
A central tenet of the amyloid cascade hypothesis is that the
accumulation of the Aβ peptides causes both cell death and
the intracellular neurofibrillary tangles. Tissue studies in vitro
have shown the toxic nature of Aβ peptide and Aβ42. Many
early studies showed that the addition of the peptide to cell
culture resulted in neuronal death and apoptosis as well as
synaptic and dendritic loss. In vivo studies produced similar
results, when these deleterious effects were seen in mouse
brains injected with the peptide. However, the relationship
between the formation of amyloid plaque and the tangles remains unclear. The aggregation of plaque initially takes place
in the frontal cortex, before spreading throughout the cortex
as the disease progresses. Neurofibrillary tangles first appear
in the limbic system, in the hippocampus and dentate gyrus.
This spatial discrepancy together with further studies that
have shown that the tangles appear before the accumulation
of plaque, and are more closely correlated with disease progression and severity have contributed to the re-evaluation of
the ACH (Braak & Braak, 1998).
An analysis conducted to determine the correlation between
cognitive abilities and some of the neurochemical and structural measurements in 15 patients with Alzheimer’s disease
further questions the relationship between amyloid plaque
and cognitive impairment. In this study, there were only weak
correlations between plaque and tangles and performance
on psychometric tests. In contrast, the density of the cortical
synapses was found to be strongly correlated with the psychological assessments of the patients (Terry et al., 1991). Mouse
models of Alzheimer’s disease have shown the accumulation
of plaques without the observed cognitive impairments. In
addition, neuroimaging analysis have shown the presence of
plaques in cognitively healthy people.
The amyloid cascade hypothesis dominates the field of
Alzheimer’s research as the most complete and evidenced
hypothesis about the causes of the disease. However, it is not
without its flaws, which has led to some reassessing the hypothesis and to others dismissing its significance altogether.
The genetic link to Alzheimer’s disease was considered the central evidence for this hypothesis. Mutations in APP, PSEN1 and
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PSEN2 are associated with familial Alzheimer’s disease and the
EPOE4 allele is a risk factor for sporadic AD. The fact that these
genes are involved in the processing of APP and the formation
of Aβ peptide has provided strong evidence for the role of amyloid plaque in disease progression. The mutations associated
with APP are all located in the proximity of the cleavage sites of
Aβ peptide, suggesting that the plaque formed by the peptide is
central to the development of the disease. However, the mutations in the presenilin genes, which encode γ-secretase, occur
throughout the protein, and not just the sites that are involved
with Aβ formation. This has led to the belief that defective APP
processing may in fact be the actual cause of the disease, and
that the formation of the Aβ peptide and plaques might just be
a secondary effect. This belief is supported by the weak correlation between plaque formation and density and cognition.While
the ACH is the best defined and most widely accepted view, the
data both for and against this hypothesis is significant. Many still
strongly support the ACH and others have dismissed it entirely
to focus on other hypotheses.

Alternative Hypotheses
Analysis of the relationship between mitochondrial function
and Alzheimer’s disease has resulted in the proposition of
the mitochondrial cascade hypothesis (MCH). The fundamental principle of the MCH is that Alzheimer’s disease is
a usual if not inevitable consequence of ageing. Support for
this hypothesis comes from the undoubted evidence of mitochondrial damage in the brains of patients with the disease. Mitochondria are critical in the regulation of cell death
and mutations in mitochondrial DNA and oxidative stress
both contribute to ageing and neurodegenerative diseases
(Lin & Beal, 2006). Studies using flourodeoxyglucose positron
emission tomography (PET) imaging, as a measure of oxygen
uptake, showed deficits in the brains of Alzheimer’s disease
patients (Jack et al., 2012). There is also strong evidence of
free radical damage in AD brains (Sonnen et al., 2008). These
findings suggest that dysfunctional and altered mitochondria
is central in the disease. Experimental evidence for the MCH
comes from studies conducted on cybrid cells- cells that
contains mitochondria from a different cell. Studies on cybrid cells which were induced to take up mitochondrial DNA
from platelets of patients with Alzheimer’s disease, showed
increased production of beta amyloid peptide (Khan et al.,
2000). This data provides support for the MCH, by showing that mitochondrial deficiency is the cause of the amyloid
plaques and central to disease development. Despite this
data, the MCH fails to explain the full array of Alzheimer’s disease pathology. In addition, genome wide association studies
have failed to show links between mitochondrial genes and
proteins and the disease. The cybrid experiments show that
mitochondrial dysregulation in Alzheimer’s disease leads to

increases in beta amyloid production. However, they do not
account for the mutations in APP and PSEN which increase
the ratio of insoluble Aβ peptide to the smaller soluble form,
or the mutations that result in an increase in aggregatory
properties.
Another hypothesis that deserves mention is the metabolism
hypothesis. According to this hypothesis, the underlying cause
of AD is hypometabolism of glucose in the brain. The basis of
this hypothesis was experiments on a rat model injected with
streptozotocin, which effects insulin production, and resulted
in decreased glucose metabolism in the brain, and learning
and memory impairments (Lannert & Hoyer 1998). Further
studies showed that the insulin signaling pathway is significantly depressed in many brain regions in Alzheimer’s disease
(Steen et al., 2005). Clinical experiments also have linked
insulin with Aβ peptide buildup. Incretin mimetics injected
in mice resulted in significant reductions in Aβ plaque load
(Mcclean & Hölscher, 2014), and there is also data that suggests that Aβ oligomers disrupt the insulin pathway leading
to an increase in glycogen synthase kinase 3β (GSK 3β), a Tau
kinase, and the formation of neurofibrillary tangles (Morgen
& Frölich, 2015). As with the mitochondrial hypothesis, no
data from genome wide association studies have confirmed
this link between Alzheimer’s disease and insulin signaling.
However, this hypothesis does provide several targets for
possible therapeutic intervention.
A more generalized proposition is the cell cycle re-entry
hypothesis. This view examines Alzheimer’s disease from
the perspective of age related DNA damage. Neurons are
post mitotic and therefore must maintain integrity long
term. Brain cells have a very high energy requirement and
therefore are particularly susceptible to DNA damage.
Mitogen kinases have increased expression in the brains
of Alzheimer’s disease patients, and have been posited to
stimulate the neurodegenerative pathways and effect cell
repair mechanisms (Arendt et al., 1995). Later studies on
differentiated neurons that were infected with the oncogenes, c-myc and ras resulted in DNA duplication and
hyperphosphorylated and unusually folded Tau proteins,
similar to those observed in Alzheimer’s disease. However,
the disrupted DNA repair mechanisms does not adequately
explain the formation of Aβ plaques, and as before there is
little support for this hypothesis from genome wide association studies.
The observation that the Alzheimer’s disease brain has a
much-reduced capillary and vascular network has led to the
formulation of the vascular hypothesis. There is much evidence linking the brain’s vascular network and the disease.
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Research has found that hypertension and diabetes, which
both have vascular effects, significantly increase the risk
of the development of the disease (Prince et al., 2014). In
one study, it was discovered that the formation of 85% of
the amyloid plaques in AD brains were either centered or
proximal to vasculature (Kumar & Singh et al., 2005). A
study of several different forms of dementia including AD
revealed substantial reductions in microvasculature (Buee
et al., 1994). Although there appears to be a credible link
between the disease and the vasculature, it is not entirely
clear if AD causes damage to the vasculature or if a vascular
insufficiency promotes deposition of Aβ plaque (Karran &
De Strooper, 2016).
One final hypothesis to consider is the Aβ oligomer hypothesis (AβOH). This theory is a variation of the original ACH.
The main traction behind this theory is that it provides possible explanation as to why the density and amount of amyloid plaques does not correlate with the symptoms of AD.
According to the AβOH the oligomers act at a distance from
the plaques and mediate their effects. There is a large amount
of data in support of this view. These include the treatment of
cells with Aβ oligomers to induce neuronal death, the impact
of the oligomers on insulin and nicotinic receptors, and the
injection of these oligomers in rat brains which induced impaired memory and cognition. The AβOH would also explain
why amyloidocentric drugs have had little success (Karran &
De Strooper, 2016).
The cholinergic hypothesis and the amyloid cascade hypothesis clearly are supported by the strongest evidence. The earliest experiments demonstrating the reduction in cholinergic
function provided the basis for much of the later research
into Alzheimer’s disease. Studies have consistently shown
reductions in the levels of enzymes responsible for acetylcholine synthesis, and loss of receptor activity disrupting its
uptake into neurons. This together with the degeneration
of cholinergic neurons has provided the basis for this hypothesis. The genetic studies into familial Alzheimer’s disease
and the link between the disease and Down’s syndrome laid
the path for the formulation of the ACH which is the most
comprehensive hypothesis in Alzheimer’s disease. The cholinergic hypothesis fails to explain the mutations in APP in
familial Alzheimer’s disease, the formation of the Aβ peptide,
amyloid plaques and neurofibrillary tangles. The Amyloid cascade hypothesis too has its inconsistencies and unanswered
questions. However, rather than rejecting the undeniable data
in support of each of these hypothesis, understanding the
links and interactions between the two may provide a clearer
picture of the mechanism of disease and provide a target for
more effective therapy.
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The connection between the cholinergic system and APP
processing has been established. In one study, human embryonic kidney (HEK) cell lines were transfected with muscarinic acetylcholine receptors. As mentioned earlier there
are five isoforms of muscarinic receptors; M1, M2, M3, M4
and M5. Cells transfected with M1 and M3 receptors showed
significant increase in the release of APPα the product in the
non-amyloidogenic pathway, when exposed to Carbachol a
muscarinic receptor agonist. These cells also released lower
levels of Aβ (Nitsch et al., 1992). Similar effects were seen in
rat cerebral cortex slices that were exposed to M1 receptor
agonists (Pittel et al., 1996). In addition to the effect the cholinergic system has on APP processing, Aβ peptides appear
to modulate cholinergic function. Picomolar and nanomolar
concentration of the beta amyloid peptide inhibit acetylcholine release from neurons in studies conducted on rat
hippocampus and cortex sections. The exact mechanism by
which the Aβ adversely effects acetylcholine release remains
unclear. However, it appears that the Aβ peptides inhibit uptake of choline in the presynaptic neurons. The activity of
choline acetyltransferase (ChAT) appears to be unaffected,
while high affinity choline uptake is decreased by 20 minutes
after incubation with Aβ (Kar et al., 2004). Further studies on
rat septal neurons found that Aβ42 reduces the levels of acetylcholine by inhibiting the activity of the enzyme pyruvate
dehydrogenase (PDH). The inhibition of pyruvate dehydrogenase results in a reduction in the biosynthesis of Acetyl-CoA,
which is critical for acetylcholine synthesis. Aβ peptides have
also been shown to disrupt cellular signaling and secondary
messengers activated by muscarinic receptors.
Aside from the disruption to the various cellular processes Aβ exposure is also toxic to neurons in the long term.
Differentiated cholinergic cell lines were the most susceptible to the toxic effects of beta amyloid, while GABAergic and
serotonergic cells were more resistant. As stated above Aβ
peptide appears to effect choline uptake in neurons. Under
conditions of choline depletion, cells synthesize acetylcholine using membrane phosphatidylcholine. Therefore, a severe
choline depletion may result in regulated membrane turnover being disrupted and eventually lead to cell death.
Aβ has also been shown to have a role in the hyper-phosphorylation of Tau. Hyper- phosphorylated Tau can no longer associate with microtubules, effecting both cell structure and vital
mechanisms of transport. In cholinergic cell lines, aggregated
Aβ peptide induced the phosphorylation of Tau proteins. The
exact mechanism is unclear but it is most likely a result of an
increase in kinase activity as Aβ peptides have been shown to
increase the activity of both MAP kinase and GSK3β.
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Figure 5 Targets of Aβ that modulate cholinergic transmission: (1)
Aβ reduces activity of pyruvate dehydrogenase, an enzyme that
generates acetyl coenzyme A (CoA) from pyruvate; (2) Aβ reduces
high-affinity uptake of choline; (3) long-term or high-dose exposure to
Aβ reduces activity of the choline acetyltransferase (ChAT) enzyme;
(4) Aβ reduces acetylcholine (ACh) content; (5) Aβ reduces ACh
release from synaptic vesicles (SV); (6) Aβ impairs muscarinic M1-like
signalling. AChE = acetylcholinesterase, Ch U = site of choline uptake,
M2 = presynaptic muscarinic M2 receptor, N = presynaptic nicotinic
receptor, PtdCho = phosphatidylcholine. (Kar et al., 2004).

Conclusion
With the wealth of evidence in support of both the cholinergic
hypothesis and the amyloid cascade hypothesis, an attempt at
fully understanding the mechanism of disease will require better
understanding of the link between Aβ peptides and the cholinergic system. The cholinergic system has been shown to play a
significant role in the regulation of APP processing. Reciprocally,
studies have found that the accumulation of Aβ peptides disrupts
the muscarinic and nicotinic receptors on cholinergic neurons
while also having a downstream effect on the signaling pathway
and secondary messengers. In addition, Aβ inhibits synthesis
of acetylcholine in a variety of ways and cholinergic neurons
are particularly susceptible to the toxic effects of Aβ peptide.
Genetics provides the basis of support for the amyloid cascade
hypothesis, and while the amyloid plaque density may not correlate well with cognitive impairment in Alzheimer’s disease, its
interactions with the cholinergic system may be responsible for
the symptoms of AD. The exact mechanism of that interaction
needs to be better elucidated, as that understanding provides
the greatest potential for more effective and targeted therapy.
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